ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?
作者信息
Murthy Venkatesh L, Koupenova Milka, Shah Ravi V
机构信息
From the Department of Medicine and Radiology, University of Michigan, Ann Arbor (V.L.M.).
Department of Medicine, University of Massachusetts Medical School, Worcester (M.K.).
出版信息
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.
Abstract
摘要
相似文献
1
ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?对抗新冠病毒：血管紧张素轴抑制在新型冠状病毒感染中能发挥作用吗？
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.
2
COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.COVID-19 与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂治疗。
Ann Intern Med. 2020 Aug 4;173(3):237-238. doi: 10.7326/M20-3047. Epub 2020 May 15.
3
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与冠状病毒
J Hypertens. 2020 Jun;38(6):1190-1191. doi: 10.1097/HJH.0000000000002469.
4
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
5
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
6
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
7
Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.血管紧张素转换酶2与炎症消退：支持继续使用处方血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Mayo Clin Proc. 2020 Jul;95(7):1552-1553. doi: 10.1016/j.mayocp.2020.05.001. Epub 2020 May 21.
8
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
9
Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?肾素-血管紧张素-醛固酮系统抑制剂用于治疗新型冠状病毒肺炎？
CMAJ. 2020 Jun 29;192(26):E728. doi: 10.1503/cmaj.76023.
10
Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.在患有非新冠病毒感染相关性脓毒症的重症监护病房患者中，血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的长期使用率很高，但死亡风险会适度增加。
Hypertension. 2020 Jun;75(6):e15-e16. doi: 10.1161/HYPERTENSIONAHA.120.15178. Epub 2020 Apr 10.
引用本文的文献
1
Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial.一项 30 天随机、平行分组、非劣效、对照试验的研究方案，旨在调查在伴有和不伴有 COVID-19 的患者中停用肾素-血管紧张素系统抑制剂的效果：RASCOVID-19 试验。
BMJ Open. 2022 Nov 30;12(11):e062895. doi: 10.1136/bmjopen-2022-062895.
2
The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle-gut-brain axis and implications for SARS-CoV-2 infection.维生素 B12 在病毒感染中的作用：对其与肌肉-肠道-大脑轴关系的综合回顾及其对 SARS-CoV-2 感染的影响。
Nutr Rev. 2022 Feb 10;80(3):561-578. doi: 10.1093/nutrit/nuab092.
3
Cardiovascular system and coronavirus disease-2019 (COVID-19): mutual injuries and unexpected outcomes.心血管系统与2019冠状病毒病（COVID-19）：相互损害与意外后果。
Egypt Heart J. 2021 Sep 3;73(1):77. doi: 10.1186/s43044-021-00202-4.
4
Navigating migraine care through the COVID-19 pandemic: an update.在 COVID-19 大流行期间管理偏头痛：更新。
J Neurol. 2021 Nov;268(11):4388-4395. doi: 10.1007/s00415-021-10610-w. Epub 2021 May 17.
5
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.使用肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 住院和死亡的关联：一项全国范围内 140 万患者的注册分析。
Eur J Heart Fail. 2021 Mar;23(3):476-485. doi: 10.1002/ejhf.2060. Epub 2020 Dec 7.
6
Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of L. (Licorice).新型冠状病毒肺炎：螺内酯与甘草干浸膏的潜在治疗意义
Front Pharmacol. 2020 Oct 22;11:558418. doi: 10.3389/fphar.2020.558418. eCollection 2020.
7
Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications.肾素-血管紧张素系统抑制在新型冠状病毒病-19 背景下：实验证据、观察性研究和临床意义。
Heart Fail Rev. 2021 Mar;26(2):381-389. doi: 10.1007/s10741-020-10022-4. Epub 2020 Sep 1.
8
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".科恩等人对关于文章《血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用与 COVID-19 住院高血压患者死亡率的关联》的信件的回应
Circ Res. 2020 Jun 5;126(12):e140-e141. doi: 10.1161/CIRCRESAHA.120.317205. Epub 2020 Jun 4.
本文引用的文献
1
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.美国心力衰竭学会/美国心脏病学会/美国心脏协会联合声明回应关于在2019冠状病毒病中使用肾素-血管紧张素-醛固酮系统拮抗剂的担忧。
J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
2
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
3
SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?严重急性呼吸综合征冠状病毒2：2019冠状病毒病患者是否应停用肾素-血管紧张素系统抑制剂？
Eur Heart J. 2020 May 14;41(19):1801-1803. doi: 10.1093/eurheartj/ehaa235.
4
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
5
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
6
Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration.肺组织 ACE2 活性降低可减弱无精氨酸缓激肽（des-Arg bradykinin）/BKB1R 轴的失活，并促进 LPS 诱导的中性粒细胞浸润。
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L17-L31. doi: 10.1152/ajplung.00498.2016. Epub 2017 Sep 21.
7
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections.血管紧张素转换酶2可预防致死性甲型H5N1禽流感感染。
Nat Commun. 2014 May 6;5:3594. doi: 10.1038/ncomms4594.
8
SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS.严重急性呼吸综合征冠状病毒对 SARS 患者心肌 ACE2 表达和炎症的调节。
Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6.
9
Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats.健康大鼠在血管紧张素转换酶（ACE）抑制和饮食钠限制期间肾血管紧张素转换酶（ACE）和血管紧张素转换酶2（ACE2）的差异调节
Exp Physiol. 2008 May;93(5):631-8. doi: 10.1113/expphysiol.2007.041855. Epub 2008 Jan 11.
10
Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat.依那普利可减轻心肌梗死大鼠心室功能障碍晚期血管紧张素转换酶2的下调。
Hypertension. 2006 Oct;48(4):572-8. doi: 10.1161/01.HYP.0000237862.94083.45. Epub 2006 Aug 14.
Zotero 插件